Since Gentles1 first reported the efficacy of griseofulvin in guinea pigs and Blank and Roth2 confirmed its usefulness in man, the value of this preparation as the first effective systemic agent for the dermatomycoses has been voluminously documented.3-9
We have studied 165 children with tinea capitis caused by Microsporum audouini, Microsporum lanosum, and Trichophyton tonsurans with various dosage schemes and have tried to correlate the trichophytin reaction to the response to griseofulvin in an effort to determine if immunological mechanisms play a role in this response.
A total of 207 children were treated, but only 165 were adequately followed, and these form the basis for this study. Of these 165 patients, 98 cases were caused by M. audouini and 4 patients had kerion. Eighty-eight were treated with griseofulvin in varying dosage; 10 were treated with 5% ammoniated mercury only as controls. Sixty-three cases were caused by M.
STRITZLER C, REIN RL, ULKU K. Tinea Capitis Treated with Griseofulvin: Evaluation of Dosage Schedules and Some Immunological Studies. Arch Dermatol. 1962;85(6):743–745. doi:10.1001/archderm.1962.01590060053011
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: